Forte Biosciences (FBRX) Total Current Liabilities (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Total Current Liabilities data on file, last reported at $23.6 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $23.6 million, up 161.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.6 million (up 161.81% YoY), and the FY2025 annual result was $20.8 million, up 128.51% from the prior year.
• Total Current Liabilities climbed to $23.6 million in Q1 2026 per FBRX's latest filing, from $20.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $23.6 million in Q1 2026 and troughed at $1.3 million in Q1 2022.
• A 5-year average of $7.9 million and a median of $7.5 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities tumbled 49.19% in 2022, then jumped 316.39% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $3.2 million in 2022, then advanced by 15.32% to $3.7 million in 2023, then surged by 147.71% to $9.1 million in 2024, then soared by 128.51% to $20.8 million in 2025, then climbed by 13.96% to $23.6 million in 2026.
• Business Quant data shows FBRX's Total Current Liabilities at $23.6 million in Q1 2026, $20.8 million in Q4 2025, and $13.0 million in Q3 2025.